|
US3252866A
(en)
|
1965-06-28 |
1966-05-24 |
Mead Johnson & Co |
2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes
|
|
US6420429B1
(en)
|
1997-12-23 |
2002-07-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Brain targeted low molecular weight hydrophobic antioxidant compounds
|
|
US5874468A
(en)
|
1996-12-26 |
1999-02-23 |
Yissum |
Brain targeted low molecular weight hydrophobic antioxidant compounds
|
|
US20030229141A1
(en)
*
|
1999-01-08 |
2003-12-11 |
Yu Ruey J. |
N-acetyl cysteine and its topical use
|
|
US20030027745A1
(en)
|
2001-06-13 |
2003-02-06 |
Repine John E. |
Diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same
|
|
BE1014949A3
(fr)
|
2001-08-14 |
2004-07-06 |
Probiox |
Procede de detection de stress oxydant et trousse pour sa mise en oeuvre.
|
|
US20060211628A1
(en)
|
2002-08-02 |
2006-09-21 |
Daphne Atlas |
Treatment of multiple sclerosis with brain targeted anti oxidant compounds
|
|
US7795203B2
(en)
|
2002-09-30 |
2010-09-14 |
Babizhayev Mark A |
Method for topical treatment of eye disease and composition and device for said treatment
|
|
JP2005350405A
(ja)
|
2004-06-11 |
2005-12-22 |
Shiseido Co Ltd |
重合抑制剤および即時型黒化防止用皮膚外用剤
|
|
CN101232877A
(zh)
*
|
2005-04-21 |
2008-07-30 |
格伦·A·戈尔茨坦 |
治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
|
|
US8993627B2
(en)
|
2005-04-21 |
2015-03-31 |
Sentient Lifesciences, Inc. |
N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
|
|
US20090234011A1
(en)
|
2005-04-21 |
2009-09-17 |
Goldstein Glenn A |
N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
|
|
JP4840804B2
(ja)
|
2006-01-20 |
2011-12-21 |
学校法人慶應義塾 |
酸化ストレスの判定方法
|
|
WO2010048716A1
(en)
|
2008-10-29 |
2010-05-06 |
Pacific Therapeutics Ltd. |
Composition and method for treating fibrosis
|
|
US20120150029A1
(en)
|
2008-12-19 |
2012-06-14 |
University Of Miami |
System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography
|
|
WO2011044230A2
(en)
*
|
2009-10-06 |
2011-04-14 |
Goldstein Glenn A |
N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
|
|
EP2397125A1
(en)
|
2010-06-15 |
2011-12-21 |
Histocell, S.L. |
Antioxidant composition
|
|
US20120142550A1
(en)
|
2010-12-06 |
2012-06-07 |
Zehnder James L |
Vanin 1 as a Peripheral Blood Oxidative Stress Sensor
|
|
WO2013138744A1
(en)
*
|
2012-03-16 |
2013-09-19 |
M. Alphabet 1, Llc |
Compositions for the treatment of skin disorders
|
|
EP2928562A4
(en)
|
2012-12-06 |
2016-06-22 |
Stealth Peptides Int Inc |
PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
|
|
US20150328337A1
(en)
|
2012-12-19 |
2015-11-19 |
The Johns Hopkins University |
Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
|
|
US9763902B2
(en)
|
2014-03-28 |
2017-09-19 |
Nacuity Pharmaceuticals, Inc |
Method for preparation of N-acetyl cysteine amide
|
|
US12472157B2
(en)
|
2014-11-07 |
2025-11-18 |
Nacuity Pharmaceuticals, Inc. |
Treatment of retinitis pigmentosa with n-acetylcysteine amide
|
|
WO2016077467A1
(en)
|
2014-11-11 |
2016-05-19 |
The Johns Hopkins University |
Biomarkers useful in the treatment of subjects having diseases of the eye
|
|
JP7418958B2
(ja)
|
2016-03-17 |
2024-01-22 |
チオジェネシス セラピューティクス， インコーポレイテッド |
システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
|
|
EP3684756A4
(en)
|
2017-09-20 |
2020-10-28 |
NaCuity Pharmaceuticals, Inc. |
SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES
|
|
JP7208982B2
(ja)
|
2017-09-20 |
2023-01-19 |
チオジェネシス セラピューティクス， インコーポレイテッド |
システアミン感受性障害の治療方法
|
|
WO2019060704A1
(en)
|
2017-09-22 |
2019-03-28 |
University Of Florida Research Foundation |
DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS
|
|
US20190135741A1
(en)
|
2017-11-09 |
2019-05-09 |
Nacuity Pharmaceuticals, Inc. |
Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
|
|
WO2019097434A1
(en)
|
2017-11-17 |
2019-05-23 |
Mahmood Piraee |
Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
|
|
CN108618993B
(zh)
*
|
2018-07-16 |
2021-07-27 |
广东格烯生物科技股份有限公司 |
一种美白组合物及其制备方法和应用
|
|
WO2020102810A1
(en)
|
2018-11-16 |
2020-05-22 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Thermoresponsive gel eye drop for ocular delivery of cysteamine
|
|
EP3908341A4
(en)
|
2019-01-11 |
2022-03-02 |
NaCuity Pharmaceuticals, Inc. |
TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
|
|
WO2020146660A1
(en)
|
2019-01-11 |
2020-07-16 |
Nacuity Pharmaceuticals, Inc. |
N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
|
|
EP3908271A4
(en)
|
2019-01-11 |
2022-10-26 |
NaCuity Pharmaceuticals, Inc. |
N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT
|